Idamycin Related Published Studies
Well-designed clinical trials related to Idamycin (Idarubicin)
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results. [2007.10]
The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. [2006.11]
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. [2005.10]
High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. [2005.08]
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. [2005.06]
Well-designed clinical trials possibly related to Idamycin (Idarubicin)
Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. [2008.08.20]
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. [2007.03]
Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial. [2006.10]
Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. [2006.09.20]
Remission induction chemotherapy induces in vivo caspase-dependent apoptosis in bone marrow acute myeloid leukemia blast cells and spares lymphocytes. [2006.05]
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study. [2006.03]
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study. [2005.12.15]
Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. [2005.12]
A randomised, double-blinded, placebo-controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients. [2005.10]
Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. [2005.08]
GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. [2005.07.15]
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. [2005.01.15]
Other research related to Idamycin (Idarubicin)
Reduced uptake of liposomal idarubicin in the perfused rat heart. [2008.08]
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. [2008.04.01]
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. [2008.04]
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. [2008.03.01]
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. [2007.07]
A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients. [2007.07]
High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. [2007.05]
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. [2007.04.01]
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. [2007.02]
Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia. [2007]
[Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia] [2006.09]
Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. [2006.05]
Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group. [2006.04]
Interaction of doxorubicin and idarubicin with red blood cells from acute myeloid leukaemia patients. [2006.02]
Effects of idarubicin and idarubicinol on rat coronary resistance and vasoconstrictor responsiveness of isolated aorta and mesentery. [2006.01]
High-dose idarubicin, busulphan and melphalan for autologous stem cell transplantation in multiple myeloma responsive to DAV chemotherapy: comparison with a historical control. [2006]
Reticulate Hyperpigmentation secondary to 5-fluorouracil and idarubicin. [2005.09]
Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. [2005.09]
Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. [2005.06.20]
A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy. [2005.04]
A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. [2005.03]
High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. [2005.01]
Phase II study of an 'all-oral' regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer--safety, efficacy and quality of life. [2005]
Other possibly related research studies
Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines. [2006.11]
Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide? [2006.11]
Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. [2006.12]
High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study. [2007.02]
Anthracycline glycosides of 2,6-dideoxy-2-fluoro-alpha-L-talopyranose. [2006.11.27]
IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience. [2006.09]
Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. [2007.01]
AmBisome treatment of fungal sinusitis in severe immunocompromised patient with acute lymphoblastic leukemia relapsed after autologous peripheral blood transplantation. [2006]
Successful treatment of retinoic acid syndrome with dexamethasone: a case report. [2005.11]
Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. [2006.07]
Donor cell leukemia developing after hematopoietic stem cell transplantation for multiple myeloma. [2006.03]
Myeloid sarcoma of the urinary bladder and epididymis as a primary manifestation of acute myeloid leukemia with inv(16). [2006.06]
Translocation between chromosome 5q35 and chromosome 11q13-- an unusual cytogenetic finding in a primary refractory acute myeloid leukemia. [2006.06]
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. [2006.05.09]
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. [2006.08.15]
The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial. [2006.05]
Dexrazoxane use in the prevention of anthracycline extravasation injury. [2006.02]
[Disappearance of a Philadelphia chromosome-positive clone and appearance of a -negative clone following treatment with imatinib mesylate in acute myelomonocytic leukemia] [2006.02]
Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer. [2006.01]
Subacute anthracycline cardiotoxicity. [2006.02]
Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B. [2005.12]
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. [2006.03.01]
Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology. [2006.04]
Posterior leukoencephalopathy after combination chemotherapy in a patient with lymphoma. [2005.12]
The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. [2005.12]
Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. [2005.12]
Improved treatment results for childhood acute myeloid leukemia in Taiwan. [2006.01]
TLS/FUS-ERG fusion gene in acute lymphoblastic leukemia with t(16;21)(p11;q22) and monitoring of minimal residual disease. [2005.12]
Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. [2005.10.20]
Treatment of acute myeloid leukemia during the second and third trimesters of pregnancy. [2005.08]
Subdural hemorrhage in a child with acute promyelocytic leukemia presenting as subtle headache. [2005.09]
[Acute myeloid leukemia with pulmonary manifestation] [2005.09]
Stem cell transplantation as consolidation therapy for children in first-remission AML: a single-center report. [2005.10]
The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. [2005]
Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart. [2006.02.08]
Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. [2005.12]
Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. [2005.12]
The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. [2005.11.03]
Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity. [2006.01]
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. [2005.11]
FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study. [2005.06]
Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients. [2005.06]
Hydatid disease in acute leukemia: effect of anticancer treatment on echinococcosis. [2005.07]
Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study. [2005.07]
IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. [2005.06]
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. [2005.08]
Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management. [2005]
Drug therapy for acute myeloid leukemia. [2005.08.15]
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. [2005.06]
Outcome of acute myeloid leukaemia in adults: a retrospective analysis. [2005.01]
Toxicity of the topoisomerase II inhibitors. [2005.03]
Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant. [2005.04]
Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia. [2005.04]
Successful salvage with high-dose sequential chemotherapy coupled with in vivo purging and autologous stem cell transplantation in 2 patients with primary refractory mantle cell lymphoma presenting in the leukemic phase. [2005.02]
In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia. [2005.03]
Acute pancreatitis during all-trans-retinoic acid treatment for acute promyelocytic leukemia in a patient without overt hypertriglyceridemia. [2005.02]
New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. [2005.02]
Acute cardiac functional and morphological changes after Anthracycline infusions in children. [2007.04.01]
Post-remission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy - results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. [2007.03.06]
The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. [2007.03]
Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. [2007.03]
|
